San Diego–based Ventyx Biosciences has what pharma wants, according to William Blair: two NLRP3 inhibitors for inflammatory ...

Immunome said on Monday its experimental drug met the main goal in a late-stage study for patients with a rare type of tumor, sending its shares up 25% in morning trade.

Immunome’s investigational oral therapy has slashed the risk of disease progression or death by 84% for patients with desmoid ...

RAHWAY, N.J.- Merck is buying a biotechnology company that's developing an experimental flu prevention drug in a $9.2 billion deal. The New Jersey based pharmaceutical giant announced on Friday its ...

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved Ezmekly (mirdametinib) for the treatment of ...

An end-of-the-year slowdown has not been witnessed by the biopharma industry yet, and certainly not in the biotech deals ...

Europe's universities and research institutes are particularly strong in biotech and pharmaceutical startups. A report from Dealroom shows that since 2022 there have been 244 academic spinouts in ...

Merck & Co Inc. is seeking to raise as much as $8 billion through a corporate bond sale, with part of the proceeds expected to help fund its proposed acquisition of Cidara Therapeutics Inc., according ...

Merck (MRK)’s stock surged by 41% over the past six months, driven not significantly by revenue, but rather by increased profits and heightened investor confidence. Following crucial Q3 earnings ...

Merck has agreed to pay a hefty premium for a biotech making a new flu prevention drug, as it braces for the expiration of the patents protecting its top-selling cancer treatment Keytruda. It is the ...

Merck has announced plans to acquire Cidara Therapeutics for $9.2 billion, or $221.50 per share. Representing a heavy premium to the biotech's prior trading price, the bid caused its shares to surge.

Merck's newest acquisition grants it access to a highly promising medicine. That could help it overcome the challenges its two biggest franchises are facing. Merck has other things going its way, ...